TY - JOUR
T1 - Decrease in circulating autotaxin by oral administration of prednisolone
AU - Sumida, Hayakazu
AU - Nakamura, Kazuhiro
AU - Yanagida, Keisuke
AU - Ohkawa, Ryunosuke
AU - Asano, Yoshihide
AU - Kadono, Takafumi
AU - Tamaki, Kunihiko
AU - Igarashi, Koji
AU - Aoki, Junken
AU - Sato, Shinichi
AU - Ishii, Satoshi
AU - Shimizu, Takao
AU - Yatomi, Yutaka
N1 - Funding Information:
This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (to H.S., K.Y., S.I., T.S., and Y.Y.) and a Global COE Program (The University of Tokyo) from the Japan Society for Promotion of Sciences (to T.S.). This research was partly supported by grants from the National Institute of Biomedical Innovation (to J.A.). We thank all other members of our laboratories for vital discussions and critical suggestions.
PY - 2013/1/16
Y1 - 2013/1/16
N2 - Background: Autotaxin (ATX), secreted mainly from adipose tissue, functions as a lysophospholipase D (lysoPLD) to hydrolyze lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). ATX-LPA signaling is implicated in a wide range of physiological and pathophysiological processes including immune response. Methods: The present study measured serum ATX antigen levels in patients with various autoimmune diseases using a recently developed automated enzyme immunoassay. In addition, serum lysoPLD activity was assessed by measuring choline liberation from the substrate LPC. Moreover, the effect of prednisolone (PSL) on mRNA expression of ATX was evaluated using cultured adipose tissue from mice. Results: Decreased serum ATX antigen levels were observed after the initiation of treatment with PSL. The decreased levels recovered during tapering of PSL dose in a dose-dependent manner without exacerbation of disease activity. Moreover, decreased ATX mRNA expression in PSL-treated cultured murine adipose tissue suggested that the effect of PSL on serum ATX may have resulted from changes in adipose tissue ATX expression. Conclusions: Our results suggest that measurement of serum ATX antigen level may be clinically useful for the assessment of steroid treatment effect and drug compliance with steroids. Furthermore, our findings provide many novel insights into the biosynthesis, physiological functions, pathological roles, and clinical significance of circulating ATX.
AB - Background: Autotaxin (ATX), secreted mainly from adipose tissue, functions as a lysophospholipase D (lysoPLD) to hydrolyze lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). ATX-LPA signaling is implicated in a wide range of physiological and pathophysiological processes including immune response. Methods: The present study measured serum ATX antigen levels in patients with various autoimmune diseases using a recently developed automated enzyme immunoassay. In addition, serum lysoPLD activity was assessed by measuring choline liberation from the substrate LPC. Moreover, the effect of prednisolone (PSL) on mRNA expression of ATX was evaluated using cultured adipose tissue from mice. Results: Decreased serum ATX antigen levels were observed after the initiation of treatment with PSL. The decreased levels recovered during tapering of PSL dose in a dose-dependent manner without exacerbation of disease activity. Moreover, decreased ATX mRNA expression in PSL-treated cultured murine adipose tissue suggested that the effect of PSL on serum ATX may have resulted from changes in adipose tissue ATX expression. Conclusions: Our results suggest that measurement of serum ATX antigen level may be clinically useful for the assessment of steroid treatment effect and drug compliance with steroids. Furthermore, our findings provide many novel insights into the biosynthesis, physiological functions, pathological roles, and clinical significance of circulating ATX.
KW - Autotaxin (ATX)
KW - Lysophosphatidic acid (LPA)
KW - Lysophospholipase D (LysoPLD)
KW - Lysophospholipid
KW - Prednisolone (PSL)
UR - http://www.scopus.com/inward/record.url?scp=84868230143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868230143&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.10.003
DO - 10.1016/j.cca.2012.10.003
M3 - Article
C2 - 23063960
AN - SCOPUS:84868230143
SN - 0009-8981
VL - 415
SP - 74
EP - 80
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -